We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

First Epigenetic Signature Test to Classify Metastasis Tumors of Unknown Origin

By LabMedica International staff writers
Posted on 06 Sep 2016
Print article
Image: The EPICUP test is designed to classify a metastasis tumor from an unknown primary origin (Photo courtesy of IDIBELL).
Image: The EPICUP test is designed to classify a metastasis tumor from an unknown primary origin (Photo courtesy of IDIBELL).
A multicentre, retrospective study has shown that an innovative new test could be used for epigenetic profiling to classify cancer of unknown primary (CUP) origin, which would enable doctors to develop more specific treatments.

Initial cancer diagnosis most often includes detection of the primary tumor and the presence or absence of metastases. However, in 5-10% of human tumors this process is done otherwise, as CUPs: metastasis is diagnosed, but the primary tumor is not detected despite various diagnostic testing.

The study, led by Prof. Dr. Manel Esteller, of Bellvitge Biomedical Research Institute (IDIBELL; Barcelona, Spain) and University of Barcelona (Barcelona, Spain), showed that it is possible to use the EPICUP test to determine the type of primary tumor responsible for the metastasis in the patient. EPICUP has helped identify up to 87% of cases of CUPs.

"A few years ago, we became aware that chemical patterns that regulate activity of genes (the epigenome) are specific to each tissue. For example, they are different in a pancreatic cell compared to a lung cell," said Dr. Manel Esteller, "We have analyzed these particular epigenetic signatures for each type of cancer in more than 10,000 human tumors. When we now study the DNA of the metastasis of a patient with a tumor of unknown origin, the photograph of the epigenome that we get will tell us that it belongs to the family of pancreatic cancer, lung, colon, breast, etc. In other words, we will give a diagnosis of the origin of the tumor.

"From now on, the patient will not be treated blindly, since we will be able to provide a much more specific therapy for this tumor type; actually, initial data shows that survival is doubled", explained Dr. Esteller, "Something very important to keep in mind is that this is not a discovery to be developed in the coming years; our collaboration with Ferrer laboratories made it possible for this test to be applied from this very moment."

The study, by Moran S et al, was published August 27, 2016, in the journal Lancet Oncology.

Related Links:
Bellvitge Biomedical Research Institute
University of Barcelona
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.